A Phase 3 open-label, randomized, active-controlled, multicenter trial to evaluate the efficacy and safety of orally administered BAY 2927088 compared with standard of care as a first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with HER2-activating mutations.

PI: Dr.ssa Arsela Prelaj 

The main purpose of this study is to learn how well BAY 2927088 works and how safe it is compared with standard treatment, in participants who have advanced NSCLC with specific genetic changes called HER2 mutations. 

The study participants will receive one of the study treatments: 

• BAY 2927088 twice every day as a tablet by mouth, or 
• Standard treatment (pembrolizumab + carboplatin/cisplatin and pemetrexed) in cycles of 21 days via infusion ("drip") into the vein.